Liraglutide was the first GLP-1 on the market, and for more than a decade it was the standard. It no longer is. What it still does, how it compares, and when it is still the right pick.
Last Updated
April 17, 2026
2010
Victoza FDA approval for type 2 diabetes (the first modern GLP-1 agonist)
~8%
Average body weight loss at 56 weeks on Saxenda (SCALE trial)
13 hours
Plasma half-life, vs 1.5 to 2 minutes for endogenous GLP-1
$250-$1,350
Monthly cost range, from generic to branded Saxenda
🔑 Key Takeaways
- Liraglutide is a once-daily GLP-1 receptor agonist sold as Victoza (type 2 diabetes) and Saxenda (chronic weight management), both from Novo Nordisk
- Approved FDA 2010 (Victoza) and 2014 (Saxenda). First GLP-1 approved in the US for weight loss
- Average weight loss of roughly 8% at 56 weeks in the SCALE trial, significantly less than semaglutide (15%) or tirzepatide (20%)
- Dose titrates from 0.6 mg daily up to 3.0 mg for weight loss or 1.8 mg for diabetes, one subcutaneous injection per day
- Approved for adolescents 12 and older with obesity (Saxenda) or type 2 diabetes in children 10 and older (Victoza, since 2019)
- Do not use if you have a personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, or are pregnant
- First generic liraglutide launched December 2024, bringing cash prices as low as ~$250/month
- When semaglutide or tirzepatide are available, liraglutide is rarely the first choice. It still fits specific scenarios: step-therapy insurance, short half-life preference, adolescent use, and lower-cost entry after generic launch
This page is the full 2026 reference for liraglutide: what it is, how it works, how it is dosed, side effects, contraindications, drug interactions, who it is right for, what it costs, and how it compares to every newer GLP-1 on the market.
What Is Liraglutide?
A daily GLP-1 agonist with two indications.
Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a synthetic analog of human GLP-1 with a fatty acid side chain that binds albumin in the bloodstream. That binding extends its half-life from the 1.5 to 2 minutes of endogenous GLP-1 out to about 13 hours, which is why it can be dosed once daily rather than continuously.
Liraglutide Brand Names and Indications
- Victoza (liraglutide 1.2 or 1.8 mg): Type 2 diabetes in adults and children age 10+
- Saxenda (liraglutide 3.0 mg): Chronic weight management in adults with BMI 30+ or 27+ with comorbidity, and adolescents 12+ with obesity
- Generic liraglutide: Launched in the US December 2024 (first generic by Hikma Pharmaceuticals)
Liraglutide has the original code name NN2211 (Novo Nordisk, 2001-2004 development period). It was approved in the EU in 2009 and the US in 2010. Saxenda followed on December 23, 2014. Pediatric diabetes approval came June 17, 2019, making it the first non-insulin diabetes drug for children approved since metformin in 2000.
What Liraglutide Is Used For
Two on-label uses, several practical ones.
- Type 2 diabetes (Victoza): Improves blood glucose control in adults and children 10+. Reduces the risk of major cardiovascular events (cardiovascular death, heart attack, stroke) in patients with established cardiovascular disease, per the LEADER trial. The ADA considers GLP-1 agonists first-line pharmacologic therapy in T2D, particularly for patients with CV disease or obesity.
- Chronic weight management (Saxenda): Approved for adults with BMI 30+ or 27+ with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia). Also approved for adolescents 12+ with BMI in the 95th percentile or higher.
- Pediatric T2D: Victoza is approved in children 10+ with type 2 diabetes who are inadequately controlled on metformin with or without insulin.
- Pediatric obesity: Saxenda is approved in adolescents 12+ with obesity. A September 2024 study showed liraglutide reduced BMI by 7.4% in children ages 6 to 12 over 56 weeks (off-label extrapolation for younger ages, not yet FDA-approved).
How Liraglutide Works
Same GLP-1 mechanism as the entire class, with a shorter half-life.
Liraglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone naturally released in response to food intake. When liraglutide activates the GLP-1 receptor at sustained therapeutic levels, four things happen:
- Insulin secretion: Pancreatic beta cells release more insulin, but only when blood glucose is elevated. This glucose-dependent mechanism is why hypoglycemia risk is low when liraglutide is used alone.
- Glucagon suppression: Alpha cells reduce glucagon release, preventing the liver from over-producing glucose after meals.
- Gastric emptying: Food moves through the stomach more slowly, prolonging satiety and reducing post-meal glucose spikes.
- Appetite regulation: GLP-1 receptors in the hypothalamus reduce hunger signaling. Most people describe appetite reduction and decreased food preoccupation within the first weeks.
Compared with newer GLP-1s like semaglutide (weekly) and tirzepatide (weekly, dual GLP-1/GIP), liraglutide produces less weight loss and requires daily dosing. It does not hit the GIP receptor, which is a key difference from tirzepatide.
Liraglutide Dosage and How to Use It
Daily subcutaneous injection, titrated slowly.
Saxenda (weight management) titration
Saxenda Dose Schedule
- Week 1: 0.6 mg once daily
- Week 2: 1.2 mg once daily
- Week 3: 1.8 mg once daily
- Week 4: 2.4 mg once daily
- Week 5 and after: 3.0 mg once daily (target maintenance dose)
Slower titration (holding a dose an extra week or two) is acceptable when GI side effects are strong. There is no requirement to move up every 7 days.
Victoza (type 2 diabetes) titration
- Week 1: 0.6 mg once daily (priming dose, not expected to improve glucose control)
- Week 2: 1.2 mg once daily
- If needed: Increase to 1.8 mg once daily
Administration
- Subcutaneous injection in the abdomen, front of thigh, or back of upper arm. Rotate injection sites.
- Can be taken any time of day, with or without food.
- Pre-filled multi-dose pen. Attach a new needle for each injection and dispose of it in a sharps container.
- Do not inject intravenously or intramuscularly.
Missed dose
- If you miss a dose and more than 12 hours remain before the next scheduled dose, take it as soon as you remember.
- If less than 12 hours remain, skip the missed dose and resume the regular schedule.
- If you miss doses for 3 or more days, contact your prescriber. You may need to restart titration from a lower dose.
Storage
- Unopened pens: Refrigerate at 2 to 8°C (36 to 46°F). Do not freeze.
- After first use: Store at room temperature (up to 30°C / 86°F) or refrigerated. Use within 30 days.
- Do not store with the needle attached. Protect from light and heat.
Liraglutide Side Effects
Mostly gastrointestinal, mostly temporary.
| Side effect | Frequency | Notes |
|---|---|---|
| Nausea | ~40% | Peaks in first 4 weeks, fades with continued use |
| Diarrhea | ~21% | Most common in first 2 weeks |
| Constipation | ~20% | Fiber, hydration, and magnesium often help |
| Vomiting | ~16% | Usually during titration |
| Headache, fatigue, dizziness | 5-15% | Often dehydration-related |
| Injection site reaction | Variable | Rotate sites to minimize |
| Hypoglycemia | Higher when combined with insulin or sulfonylureas | Adjust other diabetes medications when starting |
Serious Side Effects (Rare but Real)
- Pancreatitis: Severe, persistent abdominal pain radiating to the back. Stop the drug and seek medical attention.
- Gallbladder disease: Rapid weight loss increases gallstone risk across the class.
- Thyroid C-cell tumors: An early safety signal led to a boxed warning (thyroid tumor rate in trials was 1.3 per 1000 participant-years vs 1.0 in controls; clinical relevance in humans unknown).
- Kidney injury: Severe vomiting and dehydration can precipitate acute kidney injury.
- Angioedema and hypersensitivity: Any swelling of the face, lips, or tongue requires immediate discontinuation.
- Suicidal ideation: In January 2026 the FDA requested removal of the suicidal ideation warning from the GLP-1 RA class label after reviewing the post-marketing data. The risk is now considered no greater than placebo.
Who Should Not Use Liraglutide
Do NOT Use Liraglutide If You Have:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
- History of pancreatitis
- Severe gastroparesis or other significant GI motility disorder
- Gallbladder disease (relative contraindication, requires monitoring)
- Severe kidney or liver disease
- Pregnancy, active breastfeeding, or plans to conceive in the next 2 months
- Severe hypersensitivity to liraglutide or any component of the formulation
- Known or suspected diabetic ketoacidosis (liraglutide is not a substitute for insulin in DKA)
Liraglutide Drug Interactions
Few, but some are important.
- Insulin and sulfonylureas: Hypoglycemia risk rises substantially. Physician usually reduces insulin or sulfonylurea doses when starting liraglutide.
- Oral medications in general: Liraglutide slows gastric emptying, which can delay or reduce absorption of any oral drug taken near the injection window. Oral contraceptives, levothyroxine, and some antibiotics can be affected.
- Oral contraceptives: Reduced absorption can lower contraceptive effectiveness. Use backup contraception, especially during the first 4 weeks of each dose level.
- Warfarin: Monitor INR more frequently during the first 3 months, as weight loss and diet changes can shift anticoagulation.
- Alcohol: No direct drug interaction, but most patients tolerate alcohol noticeably less well on liraglutide.
Pregnancy, Breastfeeding, and Pediatric Use
- Pregnancy: Contraindicated. Discontinue at least 2 months before attempting to conceive. Liraglutide takes approximately 5 weeks to fully clear the body.
- Breastfeeding: Not recommended. Limited safety data in breast milk.
- Pediatric (Victoza): Approved for children 10+ with type 2 diabetes since June 2019. Dose escalation is the same as adults.
- Pediatric (Saxenda): Approved for adolescents 12+ with obesity. Target maintenance dose is 3.0 mg daily. Children may tolerate titration more slowly.
Liraglutide Cost and Insurance
2024 generic changed the picture.
| Option | Monthly cost (cash) | Notes |
|---|---|---|
| Saxenda (list price) | ~$1,350 | Without insurance or manufacturer program |
| Victoza (list price) | ~$900 | Often covered by insurance with T2D diagnosis |
| Generic liraglutide (Hikma, December 2024+) | ~$250-$500 | Available through select retail pharmacies. Pricing varies |
| Commercial insurance with prior auth | $25-$200 | Copay depends on plan tier |
| NovoCare manufacturer savings | Variable | Novo Nordisk savings card eligibility depends on insurance status |
Prior authorization is typical for Saxenda. Most commercial plans require documented BMI, a weight-related condition, and prior lifestyle intervention before approving. See the GLP-1 without insurance page for broader payment options.
Liraglutide vs Semaglutide vs Tirzepatide
Newer GLP-1s are stronger.
| Drug | Dose frequency | Average weight loss | FDA year | Best for |
|---|---|---|---|---|
| Liraglutide (Saxenda) | Daily | ~8% | 2014 | Adolescents, step therapy, short half-life preference |
| Semaglutide (Wegovy) | Weekly | ~14.9% | 2021 | Cardiovascular risk reduction, general weight loss |
| Tirzepatide (Zepbound) | Weekly | ~20.2% | 2023 | Maximum weight loss, T2D with obesity, sleep apnea |
Liraglutide produces less weight loss than semaglutide or tirzepatide, requires a daily injection instead of weekly, and offers similar cardiovascular benefit only in T2D with established CVD (LEADER trial). In head-to-head comparisons, every newer GLP-1 outperforms it on weight loss.
When Liraglutide Still Makes Sense in 2026
Specific scenarios, not general preference.
- Insurance step therapy: Many plans require a failed trial of liraglutide before approving semaglutide or tirzepatide.
- Adolescent use: Saxenda is approved from age 12 with the longest pediatric safety track record. Wegovy is also approved from 12 but with a shorter real-world history in pediatrics.
- Short half-life preference: In patients anticipating surgery or pregnancy planning in a few months, liraglutide's 13-hour half-life clears faster than semaglutide's 7-day half-life.
- Generic availability: After the December 2024 Hikma generic launch, cash price fell meaningfully below Saxenda brand. For patients paying out of pocket who want a proven GLP-1, generic liraglutide is now a realistic budget option.
- Patients who failed weekly GLP-1s for tolerance: Daily dosing spreads the GI burden more evenly than a weekly peak.
For the broader landscape of what has replaced it, see our weight loss drugs overview and the weight loss injections comparison.
Frequently Asked Questions
What is liraglutide used for?
Liraglutide is used to treat type 2 diabetes (as Victoza) and for chronic weight management (as Saxenda). Victoza is approved for adults and children 10 and older with T2D. Saxenda is approved for adults with BMI 30+ or 27+ with comorbidity, and for adolescents 12 and older with obesity.
How much weight can you lose on liraglutide?
Clinical trials show an average of about 8% body weight loss at 56 weeks on Saxenda 3.0 mg daily (SCALE trial), which is roughly 17 pounds for a 220-lb adult. Individual results vary. Semaglutide averages 15% and tirzepatide 20% in head-to-head comparisons.
Is liraglutide the same as semaglutide?
No. Both are GLP-1 receptor agonists, but liraglutide has a 13-hour half-life requiring daily dosing, while semaglutide has about a 7-day half-life allowing weekly dosing. Semaglutide produces roughly double the weight loss of liraglutide in head-to-head trials.
Is there a generic for liraglutide?
Yes. The first generic liraglutide launched December 2024 through Hikma Pharmaceuticals. Cash prices at select pharmacies run roughly $250 to $500 per month, significantly less than the $1,350 Saxenda list price.
What are the most common liraglutide side effects?
Nausea (about 40% of users), diarrhea (21%), constipation (20%), vomiting (16%), headache, and injection-site reactions. These are usually worst in the first 2 to 4 weeks and fade at the maintenance dose. Slow titration is the most effective strategy to reduce severity.
Can liraglutide be used in children?
Yes. Victoza is approved for children 10 and older with type 2 diabetes (FDA approval June 2019). Saxenda is approved for adolescents 12 and older with obesity. A 2024 study showed liraglutide reduced BMI by 7.4% in children ages 6 to 12 over 56 weeks (off-label extrapolation).
How long does liraglutide take to work?
Appetite suppression usually starts within the first week. Measurable weight loss begins within 2 to 4 weeks. A 5% weight loss threshold typically takes 3 to 6 months. Peak weight loss in trials was reached around 56 weeks. Guidelines recommend switching or stopping if 5% weight loss is not achieved after 3 to 6 months at the full dose.
What happens when you stop liraglutide?
Most patients regain a significant portion of the weight lost within 1 to 2 years of stopping. The biological mechanisms (appetite regulation, gastric emptying) return to baseline once the drug clears. Many physicians now treat obesity as a chronic condition requiring ongoing medication.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Liraglutide is a prescription medication that should be used under physician supervision. Individual results vary. Consult a licensed healthcare provider to determine whether liraglutide is appropriate for your health profile.